270 related articles for article (PubMed ID: 34934570)
1. Seropositive Muscle-Specific Tyrosine Kinase Myasthenia Gravis Presenting as a Late-Onset Isolated Sixth Nerve Palsy: A Case Report and a Brief Review of Subtypes of Myasthenia Gravis.
Park G; Kesserwani H
Cureus; 2021 Nov; 13(11):e19701. PubMed ID: 34934570
[TBL] [Abstract][Full Text] [Related]
2. Roles of collagen Q in MuSK antibody-positive myasthenia gravis.
Ohno K; Otsuka K; Ito M
Chem Biol Interact; 2016 Nov; 259(Pt B):266-270. PubMed ID: 27119269
[TBL] [Abstract][Full Text] [Related]
3. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis.
Pevzner A; Schoser B; Peters K; Cosma NC; Karakatsani A; Schalke B; Melms A; Kröger S
J Neurol; 2012 Mar; 259(3):427-35. PubMed ID: 21814823
[TBL] [Abstract][Full Text] [Related]
4. Myasthenia Gravis: From the Viewpoint of Pathogenicity Focusing on Acetylcholine Receptor Clustering, Trans-Synaptic Homeostasis and Synaptic Stability.
Takamori M
Front Mol Neurosci; 2020; 13():86. PubMed ID: 32547365
[TBL] [Abstract][Full Text] [Related]
5. Myasthenia Gravis With Antibodies Against Muscle Specific Kinase: An Update on Clinical Features, Pathophysiology and Treatment.
Cao M; Koneczny I; Vincent A
Front Mol Neurosci; 2020; 13():159. PubMed ID: 32982689
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms.
Phillips WD; Vincent A
F1000Res; 2016; 5():. PubMed ID: 27408701
[TBL] [Abstract][Full Text] [Related]
7. Specific binding of collagen Q to the neuromuscular junction is exploited to cure congenital myasthenia and to explore bases of myasthenia gravis.
Ohno K; Ito M; Kawakami Y; Krejci E; Engel AG
Chem Biol Interact; 2013 Mar; 203(1):335-40. PubMed ID: 22981737
[TBL] [Abstract][Full Text] [Related]
8. Collagen Q and anti-MuSK autoantibody competitively suppress agrin/LRP4/MuSK signaling.
Otsuka K; Ito M; Ohkawara B; Masuda A; Kawakami Y; Sahashi K; Nishida H; Mabuchi N; Takano A; Engel AG; Ohno K
Sci Rep; 2015 Sep; 5():13928. PubMed ID: 26355076
[TBL] [Abstract][Full Text] [Related]
9. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.
Hoch W; McConville J; Helms S; Newsom-Davis J; Melms A; Vincent A
Nat Med; 2001 Mar; 7(3):365-8. PubMed ID: 11231638
[TBL] [Abstract][Full Text] [Related]
10. Anti-AChR, MuSK, and LRP4 antibodies coexistence: A rare and distinct subtype of myasthenia gravis from Indian subcontinent.
Bokoliya SC; Kumar VP; Nashi S; Polavarapu K; Nalini A; Patil SA
Clin Chim Acta; 2018 Nov; 486():34-35. PubMed ID: 30006288
[TBL] [Abstract][Full Text] [Related]
11. Anti-MuSK autoantibodies block binding of collagen Q to MuSK.
Kawakami Y; Ito M; Hirayama M; Sahashi K; Ohkawara B; Masuda A; Nishida H; Mabuchi N; Engel AG; Ohno K
Neurology; 2011 Nov; 77(20):1819-26. PubMed ID: 22013178
[TBL] [Abstract][Full Text] [Related]
12. [Anti-MuSK antibodies in myasthenia gravis block binding of collagen Q to MuSK].
Ohno K
Rinsho Shinkeigaku; 2012; 52(11):1306-8. PubMed ID: 23196600
[TBL] [Abstract][Full Text] [Related]
13. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis.
Vincent A; Leite MI
Curr Opin Neurol; 2005 Oct; 18(5):519-25. PubMed ID: 16155434
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and clinical classification of autoimmune myasthenia gravis.
Berrih-Aknin S; Frenkian-Cuvelier M; Eymard B
J Autoimmun; 2014; 48-49():143-8. PubMed ID: 24530233
[TBL] [Abstract][Full Text] [Related]
15. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.
Gomez AM; Van Den Broeck J; Vrolix K; Janssen SP; Lemmens MA; Van Der Esch E; Duimel H; Frederik P; Molenaar PC; Martínez-Martínez P; De Baets MH; Losen M
Autoimmunity; 2010 Aug; 43(5-6):353-70. PubMed ID: 20380584
[TBL] [Abstract][Full Text] [Related]
16. Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.
Rivner MH; Pasnoor M; Dimachkie MM; Barohn RJ; Mei L
Neurol Clin; 2018 May; 36(2):293-310. PubMed ID: 29655451
[TBL] [Abstract][Full Text] [Related]
17. Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations.
Dresser L; Wlodarski R; Rezania K; Soliven B
J Clin Med; 2021 May; 10(11):. PubMed ID: 34064035
[TBL] [Abstract][Full Text] [Related]
18. Autoantibodies to agrin in myasthenia gravis patients.
Zhang B; Shen C; Bealmear B; Ragheb S; Xiong WC; Lewis RA; Lisak RP; Mei L
PLoS One; 2014; 9(3):e91816. PubMed ID: 24632822
[TBL] [Abstract][Full Text] [Related]
19. Myasthenia gravis: subgroup classification and therapeutic strategies.
Gilhus NE; Verschuuren JJ
Lancet Neurol; 2015 Oct; 14(10):1023-36. PubMed ID: 26376969
[TBL] [Abstract][Full Text] [Related]
20. Clinical and scientific aspects of muscle-specific tyrosine kinase-related myasthenia gravis.
Reddel SW; Morsch M; Phillips WD
Curr Opin Neurol; 2014 Oct; 27(5):558-65. PubMed ID: 25159928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
